Pharmacotherapy of adolescent substance use disorders: A review of the literature

被引:20
作者
Waxmonsky, JG
Wilens, TE
机构
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1089/cap.2005.15.810
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Substance use disorders (SUD) are increasingly conceptualized as developing during adolescence. Moreover, adolescent SUD are viewed as one of the most difficult mental health conditions to treat. The role of pharmacotherapy for adolescents with SUD is not well delineated. We systematically reviewed existing pharmacotherapy studies of adolescent SUD. Methods: A computerized search of the literature addressing the pharmacotherapy of SUD in adolescents was performed. Data from relevant peer-reviewed scientific presentations were also included. Results: Five case reports (n = 8 subjects), six open studies that primarily addressed SUD with comorbid psychiatric disorders (n = 73 subjects), and five placebo-controlled studies (n = 156 subjects) on the pharmacological treatment of youths with SUD were identified. Pharmacological agents appear to reduce comorbid psychopathology with a milder reduction in SUD symptoms. The most robust evidence exists for the treatment of SUD comorbid with affective disorders. There is a limited database supporting the use of agents to reduce substance craving and the preventative effects of pharmacotherapy on subsequent SUD development in adolescents with specific psychiatric disorders. Conclusion: Further controlled studies directed at reducing drug use and craving, and guiding the integration of pharmacotherapy and psychosocial interventions for SUD with the treatment of comorbid psychiatric illness, are necessary.
引用
收藏
页码:810 / 825
页数:16
相关论文
共 119 条
[31]   A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder [J].
DelBello, MP ;
Findling, RL ;
Kushner, S ;
Wang, D ;
Olson, WH ;
Capece, JA ;
Fazzio, L ;
Rosenthal, NR .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2005, 44 (06) :539-547
[32]   The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials [J].
Dennis, M ;
Godley, SH ;
Diamond, G ;
Tims, FM ;
Babor, T ;
Donaldson, J ;
Liddle, H ;
Titus, JC ;
Kaminer, Y ;
Webb, C ;
Hamilton, N ;
Funk, R .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2004, 27 (03) :197-213
[33]   Divalproex treatment of disruptive adolescents: A report of 10 cases [J].
Donovan, SJ ;
Susser, ES ;
Nunes, EV ;
Stewart, JW ;
Quitkin, FM ;
Klein, DF .
JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (01) :12-15
[34]  
Donovan SJ, 1996, AM J ADDICTION, V5, P181
[35]  
Donovan SJ, 1998, AM J ADDICTION, V7, P210
[36]   Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone [J].
Eap, CB ;
Bertschy, G ;
Powell, K ;
Baumann, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) :113-117
[37]   Buprenorphine or methadone for detoxification of young opioid addicts? [J].
Ebner, R ;
Schreiber, W ;
Zierer, C .
PSYCHIATRISCHE PRAXIS, 2004, 31 :S108-S110
[38]   Nontricyclic antidepressants: Current trends in children and adolescents [J].
Emslie, GJ ;
Walkup, JT ;
Pliszka, SR ;
Ernst, M .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (05) :517-528
[39]  
Fischer M, 2003, J CLIN PSYCHIAT, V64, P19
[40]   Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users [J].
Gandhi, DH ;
Jaffe, JH ;
McNary, S ;
Kavanagh, GJ ;
Hayes, M ;
Currens, M .
ADDICTION, 2003, 98 (04) :453-462